Jiangsu NHWA Pharmaceutical is developing DP-VPA in China under a strategic agreement.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
D-Pharm Ltd. (TASE: DPRM) has obtained fast track status from the China’s Food and Drug Administration (CFDA) for its epilepsy treatment, DP-VPA. D-Pharm is jointly developing the drug in China with its local partner, Jiangsu NHWA Pharmaceutical Co. Ltd., under a strategic agreement signed in 2011. D-Pharm has the right to use the Chinese data to support its development program for DP-VPA in North America and Europe.
D-Pharm discovered and is developing DP-VPA, a novel drug derived from the generic drug valproic acid, sales of which peaked at $1 billion for the treatment of epilepsy, migraine, and bipolar disorder. DP-VPA has already completed a first Phase II clinical trial.
“I’m delighted with the progress made by our partners NHWA. Advancement of DP-VPA in China is a great way to boost our own development program for DP-VPA in major pharmaceutical markets, ” said D-Pharm CEO Dr. Alex Kozak. “It enables the most efficient and effective introduction of our innovative product to the important and rapidly developing Chinese market, a feat clearly best accomplished by a competent local partner.”
NHWA is developing and will manufacture, register and sell DP-VPA for epilepsy in China, Hong Kong and Macau, in compliance with US Food and Drug Administration (FDA) standards. D-Pharm will receive milestone payments upon achievements of the development and commercial goals, as well as royalty payments from sales of DP-VPA.